Ibandronate - DrugBank

ID Pharmacology Interactions References Trials Economics Properties Spectra Taxonomy

Targets (2)

Targets (2)Biointeractions (2)

Identification

Name

Ibandronate

Accession Number

DB00710 (APRD00231, DB04635)

Type

Small Molecule

Groups

Approved, Investigational

Description

Ibandronate is a nitrogen-containing bisphosphonate in the same class as alendronate and risedronate. Ibandronate inhibits osteoclast-mediated bone resorption. All of the bisphosphonates prevent the breakdown of bone by bone cells called osteoclasts. In persons who are at high risk for osteoporosis, bisphosphonates not only result in increased amounts of bone and bone strength, they also reduce the risk of hip fractures and other bone fractures.

Structure

MOL SDF 3D-SDF PDB SMILES InChI View 3D Structure

Synonyms

Bondronat

Ibandronic Acid

External IDs

R484

Product Ingredients

Ingredient	UNII	CAS	InChI Key	Details
Ibandronate sodium	J12U072QL0	138926-19-9	LXLBEOAZMZAZND-UHFFFAOYNA-M	Details

Product Images

Approved Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Bondronat	Liquid	1 mg	Intravenous	Hoffmann La Roche	2004-05-31	2006-05-17	Canada
Boniva	Tablet, film coated	150 mg/1	Oral	Physicians Total Care, Inc.	2005-06-02	Not applicable	US
Boniva	Tablet, film coated	150 mg/1	Oral	Genentech, Inc.	2002-07-15	Not applicable	US
Boniva	Injection, solution	3 mg/3mL	Intravenous	Genentech, Inc.	2011-06-01	Not applicable	US
Bonviva	Tablet, film coated	150 mg	Oral	Roche Registration Limited	2004-02-23	Not applicable	EU
Bonviva	Injection, solution	3 mg	Intravenous	Roche Registration Limited	2004-02-23	Not applicable	EU
Bonviva	Tablet, film coated	150 mg	Oral	Roche Registration Limited	2004-02-23	Not applicable	EU
Bonviva	Injection, solution	3 mg	Intravenous	Roche Registration Limited	2004-02-23	Not applicable	EU

Approved Generic Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Iasibon	Injection, solution, concentrate	6 mg	Intravenous	Pharmathen S.A.	2011-01-21	Not applicable	EU
Iasibon	Injection, solution, concentrate	1 mg	Intravenous	Pharmathen S.A.	2011-01-21	Not applicable	EU
Iasibon	Tablet, film coated	50 mg	Oral	Pharmathen S.A.	2011-01-21	Not applicable	EU
Iasibon	Injection, solution, concentrate	6 mg	Intravenous	Pharmathen S.A.	2011-01-21	Not applicable	EU
Iasibon	Tablet, film coated	50 mg	Oral	Pharmathen S.A.	2011-01-21	Not applicable	EU
Iasibon	Injection, solution, concentrate	2 mg	Intravenous	Pharmathen S.A.	2011-01-21	Not applicable	EU
Iasibon	Tablet, film coated	50 mg	Oral	Pharmathen S.A.	2011-01-21	Not applicable	EU
Iasibon	Tablet, film coated	50 mg	Oral	Pharmathen S.A.	2011-01-21	Not applicable	EU
Iasibon	Tablet, film coated	50 mg	Oral	Pharmathen S.A.	2011-01-21	Not applicable	EU
Iasibon	Injection, solution, concentrate	6 mg	Intravenous	Pharmathen S.A.	2011-01-21	Not applicable	EU
Ibandronate Sodium	Tablet, film coated	150 mg/1	Oral	Apotex Corporation	2012-03-19	Not applicable	US
Ibandronate Sodium	Injection, solution	3 mg/3mL	Intravenous	Heritage	2014-09-04	Not applicable	US
Ibandronate Sodium	Injection, solution	3 mg/3mL	Intravenous	Auro Medics Pharma Llc	2015-08-19	Not applicable	US
Ibandronate Sodium	Tablet, film coated	150 mg/1	Oral	Aurobindo Pharma	2016-03-11	Not applicable	US
Ibandronate Sodium	Tablet	150 mg/1	Oral	Actavis Pharma Company	2012-03-20	Not applicable	US
Ibandronate Sodium	Tablet	150 mg/1	Oral	Dr Reddy's Laboratories	2012-06-21	Not applicable	US
Ibandronate Sodium	Tablet	150 mg/1	Oral	Av Kare, Inc.	2013-12-04	2016-10-13	US
Ibandronate Sodium	Injection, solution	3 mg/3mL	Intravenous	Sun Pharmaceutical Industries Limited	2014-02-15	Not applicable	US
Ibandronate Sodium	Injection, solution	3 mg/3mL	Intravenous	Accord Healthcare Limited	2016-08-15	2017-01-27	US
Ibandronate Sodium	Injection	3 mg/3mL	Intravenous	Apotex Corporation	2016-01-13	Not applicable	US
Ibandronate Sodium	Injection, solution	3 mg/3mL	Intravenous	Sagent Pharmaceuticals	2014-09-02	Not applicable	US
Ibandronate Sodium	Tablet	150 mg/1	Oral	Alvogen, Inc.	2014-05-01	Not applicable	US
Ibandronate Sodium	Injection, solution	3 mg/3mL	Intravenous	Mylan Institutional	2014-09-02	Not applicable	US
Ibandronate Sodium	Tablet, film coated	150 mg/1	Oral	Golden State Medical Supply	2016-02-05	Not applicable	US
Ibandronic Acid Accord	Injection, solution	3 mg	Intravenous	Accord Healthcare Limited	2012-11-19	Not applicable	EU
Ibandronic Acid Accord	Injection, solution, concentrate	6 mg	Intravenous	Accord Healthcare Limited	2012-11-19	Not applicable	EU
Ibandronic Acid Accord	Injection, solution	3 mg	Intravenous	Accord Healthcare Limited	2012-11-19	Not applicable	EU
Ibandronic Acid Accord	Injection, solution, concentrate	2 mg	Intravenous	Accord Healthcare Limited	2012-11-19	Not applicable	EU
Ibandronic Acid Accord	Injection, solution, concentrate	6 mg	Intravenous	Accord Healthcare Limited	2012-11-19	Not applicable	EU
Ibandronic Acid Accord	Injection, solution, concentrate	6 mg	Intravenous	Accord Healthcare Limited	2012-11-19	Not applicable	EU
Ibandronic Acid Sandoz	Tablet, film coated	50 mg	Oral	Sandoz	2011-07-26	Not applicable	EU
Ibandronic Acid Sandoz	Tablet, film coated	50 mg	Oral	Sandoz	2011-07-26	Not applicable	EU
Ibandronic Acid Sandoz	Tablet, film coated	50 mg	Oral	Sandoz	2011-07-26	Not applicable	EU
Ibandronic Acid Sandoz	Tablet, film coated	50 mg	Oral	Sandoz	2011-07-26	Not applicable	EU
Ibandronic Acid Sandoz	Tablet, film coated	50 mg	Oral	Sandoz	2011-07-26	Not applicable	EU

Approved Over the Counter Products

Not Available

Unapproved/Other Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Bondenza	Tablet, film coated	150 mg	Oral	Roche Registration Limited	2004-02-23	Not applicable	EU
Bondenza	Injection, solution	3 mg	Intravenous	Roche Registration Limited	2004-02-23	Not applicable	EU
Bondenza	Tablet, film coated	150 mg	Oral	Roche Registration Limited	2004-02-23	Not applicable	EU
Bondenza	Injection, solution	3 mg	Intravenous	Roche Registration Limited	2004-02-23	Not applicable	EU

International Brands

Name	Company
ADRONiL	Not Available
Bonviva	Not Available

Brand mixtures

Not Available

Categories

UNII

UMD7G2653W

CAS number

114084-78-5

Weight

Average: 319.2289
Monoisotopic: 319.094975119

Chemical Formula

C₉H₂₃NO₇P₂

InChI Key

MPBVHIBUJCELCL-UHFFFAOYSA-N

InChI

InChI=1S/C9H23NO7P2/c1-3-4-5-7-10(2)8-6-9(11,18(12,13)14)19(15,16)17/h11H,3-8H2,1-2H3,(H2,12,13,14)(H2,15,16,17)

IUPAC Name

{1-hydroxy-3-[methyl(pentyl)amino]-1-phosphonopropyl}phosphonic acid

SMILES

CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O

Pharmacology

Indication

For the treatment and prevention of osteoporosis in postmenopausal women.

Structured Indications

Pharmacodynamics

Mechanism of action

The action of ibandronate on bone tissue is based partly on its affinity for hydroxyapatite, which is part of the mineral matrix of bone. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting farnesyl pyrophosphate (FPP) synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.

Target	Kind	Pharmacological action	Actions	Organism	UniProt ID
Farnesyl pyrophosphate synthase	Protein	yes	inhibitor	Human	P14324	details
Hydroxylapatite	Small molecule	yes	antagonist	Human	not applicable	details

Absorption

Poorly absorbed (mean bioavailability following a 2.5 mg oral dose is about 0.6% compared to intravenous dosing). Absorption is impaired by any kind of food or drink other than plain water.

Volume of distribution

90 L

Protein binding

90.9 to 99.5% over an ibandronate concentration range of 2 to 10 ng/mL

Metabolism

No evidence of ibandronate being metabolized in humans.

Route of elimination

Ibandronate is eliminated by renal excretion. Unabsorbed ibandronate is eliminated unchanged in the feces.

Half life

10-60 hours

Clearance

84 to 160 mL/min [IV administration]

Toxicity

LD₅₀ = 811 mg/kg (rat, oral), side effects include bronchitis, pneumonia and urinary tract infections.

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
Aceclofenac	The risk or severity of adverse effects can be increased when Aceclofenac is combined with Ibandronate.	Approved
Acetylsalicylic acid	The risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Ibandronate.	Approved, Vet Approved
Aclarubicin	Aclarubicin may increase the hypocalcemic activities of Ibandronate.	Investigational
Adapalene	The risk or severity of adverse effects can be increased when Adapalene is combined with Ibandronate.	Approved
Aluminum hydroxide	The serum concentration of Ibandronate can be decreased when it is combined with Aluminum hydroxide.	Approved
Amikacin	Amikacin may increase the hypocalcemic activities of Ibandronate.	Approved, Vet Approved
Amiodarone	Ibandronate may increase the QTc-prolonging activities of Amiodarone.	Approved, Investigational
Amrubicin	Amrubicin may increase the hypocalcemic activities of Ibandronate.	Approved, Investigational
Anagrelide	Ibandronate may increase the QTc-prolonging activities of Anagrelide.	Approved
Andrographolide	The risk or severity of adverse effects can be increased when HMPL-004 is combined with Ibandronate.	Investigational
Anisodamine	The risk or severity of adverse effects can be increased when Anisodamine is combined with Ibandronate.	Investigational
Antipyrine	The risk or severity of adverse effects can be increased when Antipyrine is combined with Ibandronate.	Approved
Apocynin	The risk or severity of adverse effects can be increased when Acetovanillone is combined with Ibandronate.	Investigational
Apramycin	Apramycin may increase the hypocalcemic activities of Ibandronate.	Experimental, Vet Approved
Apremilast	The risk or severity of adverse effects can be increased when Apremilast is combined with Ibandronate.	Approved, Investigational
Arbekacin	Arbekacin may increase the hypocalcemic activities of Ibandronate.	Approved
Arsenic trioxide	Ibandronate may increase the QTc-prolonging activities of Arsenic trioxide.	Approved, Investigational
Artemether	Ibandronate may increase the QTc-prolonging activities of Artemether.	Approved
Asenapine	Ibandronate may increase the QTc-prolonging activities of Asenapine.	Approved
Azapropazone	The risk or severity of adverse effects can be increased when Azapropazone is combined with Ibandronate.	Withdrawn
Azelastine	The risk or severity of adverse effects can be increased when Azelastine is combined with Ibandronate.	Approved
Azithromycin	Ibandronate may increase the QTc-prolonging activities of Azithromycin.	Approved
Balsalazide	The risk or severity of adverse effects can be increased when Balsalazide is combined with Ibandronate.	Approved, Investigational
Bedaquiline	Ibandronate may increase the QTc-prolonging activities of Bedaquiline.	Approved
Benoxaprofen	The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Ibandronate.	Withdrawn
Betulinic Acid	The risk or severity of adverse effects can be increased when Betulinic Acid is combined with Ibandronate.	Investigational
Bismuth Subcitrate	The serum concentration of Ibandronate can be decreased when it is combined with Bismuth Subcitrate.	Approved
Bromfenac	The risk or severity of adverse effects can be increased when Bromfenac is combined with Ibandronate.	Approved
Bucillamine	The risk or severity of adverse effects can be increased when Bucillamine is combined with Ibandronate.	Investigational
Calcium	The serum concentration of Ibandronate can be decreased when it is combined with Calcium.	Nutraceutical
Calcium Acetate	The serum concentration of Ibandronate can be decreased when it is combined with Calcium Acetate.	Approved
Calcium Carbonate	The serum concentration of Ibandronate can be decreased when it is combined with Calcium carbonate.	Approved
Calcium Chloride	The serum concentration of Ibandronate can be decreased when it is combined with Calcium Chloride.	Approved
Calcium Citrate	The serum concentration of Ibandronate can be decreased when it is combined with Calcium citrate.	Approved
Calcium glubionate	The serum concentration of Ibandronate can be decreased when it is combined with Calcium glubionate.	Approved
Calcium Gluceptate	The serum concentration of Ibandronate can be decreased when it is combined with Calcium Gluceptate.	Approved
Calcium gluconate	The serum concentration of Ibandronate can be decreased when it is combined with Calcium gluconate.	Approved, Vet Approved
Carprofen	The risk or severity of adverse effects can be increased when Carprofen is combined with Ibandronate.	Approved, Vet Approved, Withdrawn
Castanospermine	The risk or severity of adverse effects can be increased when Castanospermine is combined with Ibandronate.	Experimental
Celecoxib	The risk or severity of adverse effects can be increased when Celecoxib is combined with Ibandronate.	Approved, Investigational
Ceritinib	Ibandronate may increase the QTc-prolonging activities of Ceritinib.	Approved
Chloroquine	Ibandronate may increase the QTc-prolonging activities of Chloroquine.	Approved, Vet Approved
Chlorpromazine	Ibandronate may increase the QTc-prolonging activities of Chlorpromazine.	Approved, Vet Approved
Choline magnesium trisalicylate	The risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Ibandronate.	Approved
Ciprofloxacin	Ibandronate may increase the QTc-prolonging activities of Ciprofloxacin.	Approved, Investigational
Cisapride	Ibandronate may increase the QTc-prolonging activities of Cisapride.	Approved, Investigational, Withdrawn
Citalopram	Ibandronate may increase the QTc-prolonging activities of Citalopram.	Approved
Clarithromycin	Ibandronate may increase the QTc-prolonging activities of Clarithromycin.	Approved
Clonixin	The risk or severity of adverse effects can be increased when Clonixin is combined with Ibandronate.	Approved
Clozapine	Ibandronate may increase the QTc-prolonging activities of Clozapine.	Approved
Crizotinib	Ibandronate may increase the QTc-prolonging activities of Crizotinib.	Approved
Curcumin	The risk or severity of adverse effects can be increased when Curcumin is combined with Ibandronate.	Investigational
Daunorubicin	Daunorubicin may increase the hypocalcemic activities of Ibandronate.	Approved
Deferasirox	The risk or severity of adverse effects can be increased when Ibandronate is combined with Deferasirox.	Approved, Investigational
Dexlansoprazole	The therapeutic efficacy of Ibandronate can be decreased when used in combination with TAK-390MR.	Approved
Diclofenac	The risk or severity of adverse effects can be increased when Diclofenac is combined with Ibandronate.	Approved, Vet Approved
Diflunisal	The risk or severity of adverse effects can be increased when Diflunisal is combined with Ibandronate.	Approved
Disopyramide	Ibandronate may increase the QTc-prolonging activities of Disopyramide.	Approved
Dofetilide	Ibandronate may increase the QTc-prolonging activities of Dofetilide.	Approved
Dolasetron	Ibandronate may increase the QTc-prolonging activities of Dolasetron.	Approved
Domperidone	Ibandronate may increase the QTc-prolonging activities of Domperidone.	Approved, Investigational, Vet Approved
Doxorubicin	Doxorubicin may increase the hypocalcemic activities of Ibandronate.	Approved, Investigational
Dronedarone	Ibandronate may increase the QTc-prolonging activities of Dronedarone.	Approved
Droperidol	Ibandronate may increase the QTc-prolonging activities of Droperidol.	Approved, Vet Approved
Droxicam	The risk or severity of adverse effects can be increased when Droxicam is combined with Ibandronate.	Approved
Duvelisib	The risk or severity of adverse effects can be increased when Duvelisib is combined with Ibandronate.	Investigational
E-6201	The risk or severity of adverse effects can be increased when E6201 is combined with Ibandronate.	Investigational
Ebselen	The risk or severity of adverse effects can be increased when Ebselen is combined with Ibandronate.	Investigational
Eliglustat	Ibandronate may increase the QTc-prolonging activities of Eliglustat.	Approved
Epirizole	The risk or severity of adverse effects can be increased when Epirizole is combined with Ibandronate.	Approved
Epirubicin	Epirubicin may increase the hypocalcemic activities of Ibandronate.	Approved
Erythromycin	Ibandronate may increase the QTc-prolonging activities of Erythromycin.	Approved, Vet Approved
Escitalopram	Ibandronate may increase the QTc-prolonging activities of Escitalopram.	Approved, Investigational
Esomeprazole	The therapeutic efficacy of Ibandronate can be decreased when used in combination with Esomeprazole.	Approved, Investigational
Etanercept	The risk or severity of adverse effects can be increased when Etanercept is combined with Ibandronate.	Approved, Investigational
Etodolac	The risk or severity of adverse effects can be increased when Etodolac is combined with Ibandronate.	Approved, Investigational, Vet Approved
Etofenamate	The risk or severity of adverse effects can be increased when Etofenamate is combined with Ibandronate.	Approved
Etoricoxib	The risk or severity of adverse effects can be increased when Etoricoxib is combined with Ibandronate.	Approved, Investigational
Fenbufen	The risk or severity of adverse effects can be increased when Fenbufen is combined with Ibandronate.	Approved
Fenoprofen	The risk or severity of adverse effects can be increased when Fenoprofen is combined with Ibandronate.	Approved
Ferric Citrate	The serum concentration of Ibandronate can be decreased when it is combined with Ferric Citrate.	Approved
Flecainide	Ibandronate may increase the QTc-prolonging activities of Flecainide.	Approved, Withdrawn
Floctafenine	The risk or severity of adverse effects can be increased when Floctafenine is combined with Ibandronate.	Approved, Withdrawn
Fluoxetine	Ibandronate may increase the QTc-prolonging activities of Fluoxetine.	Approved, Vet Approved
Flupentixol	Ibandronate may increase the QTc-prolonging activities of Flupentixol.	Approved, Withdrawn
Flurbiprofen	The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Ibandronate.	Approved, Investigational
Framycetin	Framycetin may increase the hypocalcemic activities of Ibandronate.	Approved
Gadobenic acid	Ibandronate may increase the QTc-prolonging activities of Gadobenic acid.	Approved
Gemifloxacin	Ibandronate may increase the QTc-prolonging activities of Gemifloxacin.	Approved, Investigational
Geneticin	Geneticin may increase the hypocalcemic activities of Ibandronate.	Experimental
Gentamicin	Gentamicin may increase the hypocalcemic activities of Ibandronate.	Approved, Vet Approved
GENTAMICIN C1A	GENTAMICIN C1A may increase the hypocalcemic activities of Ibandronate.	Experimental
Goserelin	Ibandronate may increase the QTc-prolonging activities of Goserelin.	Approved
Granisetron	Ibandronate may increase the QTc-prolonging activities of Granisetron.	Approved, Investigational
Haloperidol	Ibandronate may increase the QTc-prolonging activities of Haloperidol.	Approved
Higenamine	The risk or severity of adverse effects can be increased when Higenamine is combined with Ibandronate.	Investigational
Ibuprofen	The risk or severity of adverse effects can be increased when Ibuprofen is combined with Ibandronate.	Approved
Ibuproxam	The risk or severity of adverse effects can be increased when Ibuproxam is combined with Ibandronate.	Withdrawn
Ibutilide	Ibandronate may increase the QTc-prolonging activities of Ibutilide.	Approved
Icatibant	The risk or severity of adverse effects can be increased when Icatibant is combined with Ibandronate.	Approved
Idarubicin	Idarubicin may increase the hypocalcemic activities of Ibandronate.	Approved
Iloperidone	Ibandronate may increase the QTc-prolonging activities of Iloperidone.	Approved
Indomethacin	The risk or severity of adverse effects can be increased when Indomethacin is combined with Ibandronate.	Approved, Investigational
Indoprofen	The risk or severity of adverse effects can be increased when Indoprofen is combined with Ibandronate.	Withdrawn
Iron saccharate	The serum concentration of Ibandronate can be decreased when it is combined with Iron saccharate.	Approved
Isoxicam	The risk or severity of adverse effects can be increased when Isoxicam is combined with Ibandronate.	Withdrawn
Kanamycin	Kanamycin may increase the hypocalcemic activities of Ibandronate.	Approved, Vet Approved
Kebuzone	The risk or severity of adverse effects can be increased when Kebuzone is combined with Ibandronate.	Experimental
Ketoprofen	The risk or severity of adverse effects can be increased when Ketoprofen is combined with Ibandronate.	Approved, Vet Approved
Ketorolac	The risk or severity of adverse effects can be increased when Ketorolac is combined with Ibandronate.	Approved
Lansoprazole	The therapeutic efficacy of Ibandronate can be decreased when used in combination with Lansoprazole.	Approved, Investigational
Leflunomide	The risk or severity of adverse effects can be increased when Leflunomide is combined with Ibandronate.	Approved, Investigational
Lenvatinib	Ibandronate may increase the QTc-prolonging activities of Lenvatinib.	Approved
Leuprolide	Ibandronate may increase the QTc-prolonging activities of Leuprolide.	Approved, Investigational
Levofloxacin	Ibandronate may increase the QTc-prolonging activities of Levofloxacin.	Approved, Investigational
Lisofylline	The risk or severity of adverse effects can be increased when Lisofylline is combined with Ibandronate.	Investigational
Lopinavir	Ibandronate may increase the QTc-prolonging activities of Lopinavir.	Approved
Lornoxicam	The risk or severity of adverse effects can be increased when Lornoxicam is combined with Ibandronate.	Approved
Loxoprofen	The risk or severity of adverse effects can be increased when Loxoprofen is combined with Ibandronate.	Approved
Lumefantrine	Ibandronate may increase the QTc-prolonging activities of Lumefantrine.	Approved
Lumiracoxib	The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Ibandronate.	Approved, Investigational
Magnesium carbonate	The serum concentration of Ibandronate can be decreased when it is combined with Magnesium carbonate.	Approved
Magnesium Hydroxide	The serum concentration of Ibandronate can be decreased when it is combined with Magnesium hydroxide.	Approved
Magnesium oxide	The serum concentration of Ibandronate can be decreased when it is combined with Magnesium oxide.	Approved
Magnesium salicylate	The serum concentration of Ibandronate can be decreased when it is combined with Magnesium salicylate.	Approved
Magnesium Sulfate	The serum concentration of Ibandronate can be decreased when it is combined with Magnesium Sulfate.	Approved, Vet Approved
Magnesium Trisilicate	The serum concentration of Ibandronate can be decreased when it is combined with Magnesium Trisilicate.	Approved
Masoprocol	The risk or severity of adverse effects can be increased when Masoprocol is combined with Ibandronate.	Approved
Meclofenamic acid	The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Ibandronate.	Approved, Vet Approved
Mefenamic acid	The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Ibandronate.	Approved
Meloxicam	The risk or severity of adverse effects can be increased when Meloxicam is combined with Ibandronate.	Approved, Vet Approved
Mesalazine	The risk or severity of adverse effects can be increased when Mesalazine is combined with Ibandronate.	Approved
Metamizole	The risk or severity of adverse effects can be increased when Metamizole is combined with Ibandronate.	Withdrawn
Methadone	Ibandronate may increase the QTc-prolonging activities of Methadone.	Approved
Metrizamide	Metrizamide may increase the hypocalcemic activities of Ibandronate.	Approved
Mifepristone	Mifepristone may increase the QTc-prolonging activities of Ibandronate.	Approved, Investigational
Mizoribine	The risk or severity of adverse effects can be increased when Mizoribine is combined with Ibandronate.	Investigational
Moxifloxacin	Ibandronate may increase the QTc-prolonging activities of Moxifloxacin.	Approved, Investigational
Mycophenolate mofetil	The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Ibandronate.	Approved, Investigational
Mycophenolic acid	The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Ibandronate.	Approved
Nabumetone	The risk or severity of adverse effects can be increased when Nabumetone is combined with Ibandronate.	Approved
Nafamostat	The risk or severity of adverse effects can be increased when Nafamostat is combined with Ibandronate.	Approved, Investigational
Naftifine	The risk or severity of adverse effects can be increased when Naftifine is combined with Ibandronate.	Approved
Naproxen	The risk or severity of adverse effects can be increased when Naproxen is combined with Ibandronate.	Approved, Vet Approved
Neamine	Neamine may increase the hypocalcemic activities of Ibandronate.	Experimental
Neomycin	Neomycin may increase the hypocalcemic activities of Ibandronate.	Approved, Vet Approved
Nepafenac	The risk or severity of adverse effects can be increased when Nepafenac is combined with Ibandronate.	Approved
Netilmicin	Netilmicin may increase the hypocalcemic activities of Ibandronate.	Approved
Niflumic Acid	The risk or severity of adverse effects can be increased when Niflumic Acid is combined with Ibandronate.	Approved
Nilotinib	Ibandronate may increase the QTc-prolonging activities of Nilotinib.	Approved, Investigational
Nimesulide	The risk or severity of adverse effects can be increased when Nimesulide is combined with Ibandronate.	Approved, Withdrawn
Nitroaspirin	The risk or severity of adverse effects can be increased when Nitroaspirin is combined with Ibandronate.	Investigational
Ofloxacin	Ibandronate may increase the QTc-prolonging activities of Ofloxacin.	Approved
Olopatadine	The risk or severity of adverse effects can be increased when Olopatadine is combined with Ibandronate.	Approved
Olsalazine	The risk or severity of adverse effects can be increased when Olsalazine is combined with Ibandronate.	Approved
Omeprazole	The therapeutic efficacy of Ibandronate can be decreased when used in combination with Omeprazole.	Approved, Investigational, Vet Approved
Ondansetron	Ibandronate may increase the QTc-prolonging activities of Ondansetron.	Approved
Oxaprozin	The risk or severity of adverse effects can be increased when Oxaprozin is combined with Ibandronate.	Approved
Oxyphenbutazone	The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Ibandronate.	Withdrawn
Paliperidone	Ibandronate may increase the QTc-prolonging activities of Paliperidone.	Approved
Panobinostat	Ibandronate may increase the QTc-prolonging activities of Panobinostat.	Approved, Investigational
Pantoprazole	The therapeutic efficacy of Ibandronate can be decreased when used in combination with Pantoprazole.	Approved
Parecoxib	The risk or severity of adverse effects can be increased when Parecoxib is combined with Ibandronate.	Approved
Paromomycin	Paromomycin may increase the hypocalcemic activities of Ibandronate.	Approved, Investigational
Pazopanib	Ibandronate may increase the QTc-prolonging activities of Pazopanib.	Approved
Pentamidine	Ibandronate may increase the QTc-prolonging activities of Pentamidine.	Approved
Perflutren	Ibandronate may increase the QTc-prolonging activities of Perflutren.	Approved
Phenylbutazone	The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Ibandronate.	Approved, Vet Approved
Pimecrolimus	The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Ibandronate.	Approved, Investigational
Pimozide	Ibandronate may increase the QTc-prolonging activities of Pimozide.	Approved
Pirarubicin	Pirarubicin may increase the hypocalcemic activities of Ibandronate.	Investigational
Pirfenidone	The risk or severity of adverse effects can be increased when Pirfenidone is combined with Ibandronate.	Investigational
Piroxicam	The risk or severity of adverse effects can be increased when Piroxicam is combined with Ibandronate.	Approved, Investigational
Plicamycin	Plicamycin may increase the hypocalcemic activities of Ibandronate.	Approved, Withdrawn
Primaquine	Ibandronate may increase the QTc-prolonging activities of Primaquine.	Approved
Procainamide	Ibandronate may increase the QTc-prolonging activities of Procainamide.	Approved
Promazine	Ibandronate may increase the QTc-prolonging activities of Promazine.	Approved, Vet Approved
Propacetamol	The risk or severity of adverse effects can be increased when Propacetamol is combined with Ibandronate.	Approved
Propafenone	Ibandronate may increase the QTc-prolonging activities of Propafenone.	Approved
PTC299	The risk or severity of adverse effects can be increased when PTC299 is combined with Ibandronate.	Investigational
Puromycin	Puromycin may increase the hypocalcemic activities of Ibandronate.	Experimental
Quetiapine	Ibandronate may increase the QTc-prolonging activities of Quetiapine.	Approved
Quinidine	Ibandronate may increase the QTc-prolonging activities of Quinidine.	Approved
Quinine	Ibandronate may increase the QTc-prolonging activities of Quinine.	Approved
Rabeprazole	The therapeutic efficacy of Ibandronate can be decreased when used in combination with Rabeprazole.	Approved, Investigational
Resveratrol	The risk or severity of adverse effects can be increased when Resveratrol is combined with Ibandronate.	Experimental, Investigational
Ribostamycin	Ribostamycin may increase the hypocalcemic activities of Ibandronate.	Approved
Rofecoxib	The risk or severity of adverse effects can be increased when Rofecoxib is combined with Ibandronate.	Investigational, Withdrawn
Salicylamide	The risk or severity of adverse effects can be increased when Salicylamide is combined with Ibandronate.	Approved
Salicylic acid	The risk or severity of adverse effects can be increased when Salicylic acid is combined with Ibandronate.	Approved, Vet Approved
Salsalate	The risk or severity of adverse effects can be increased when Salsalate is combined with Ibandronate.	Approved
Saquinavir	Ibandronate may increase the QTc-prolonging activities of Saquinavir.	Approved, Investigational
Sisomicin	Sisomicin may increase the hypocalcemic activities of Ibandronate.	Investigational
Sotalol	Ibandronate may increase the QTc-prolonging activities of Sotalol.	Approved
SP1049C	SP1049C may increase the hypocalcemic activities of Ibandronate.	Investigational
Spectinomycin	Spectinomycin may increase the hypocalcemic activities of Ibandronate.	Approved, Vet Approved
SRT501	The risk or severity of adverse effects can be increased when SRT501 is combined with Ibandronate.	Investigational
Streptomycin	Streptomycin may increase the hypocalcemic activities of Ibandronate.	Approved, Vet Approved
Streptozocin	Streptozocin may increase the hypocalcemic activities of Ibandronate.	Approved
Sulfasalazine	The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Ibandronate.	Approved
Sulfisoxazole	Ibandronate may increase the QTc-prolonging activities of Sulfisoxazole.	Approved, Vet Approved
Sulindac	The risk or severity of adverse effects can be increased when Sulindac is combined with Ibandronate.	Approved
Suprofen	The risk or severity of adverse effects can be increased when Suprofen is combined with Ibandronate.	Approved, Withdrawn
Telavancin	Ibandronate may increase the QTc-prolonging activities of Telavancin.	Approved
Telithromycin	Ibandronate may increase the QTc-prolonging activities of Telithromycin.	Approved
Tenoxicam	The risk or severity of adverse effects can be increased when Tenoxicam is combined with Ibandronate.	Approved
Teriflunomide	The risk or severity of adverse effects can be increased when Teriflunomide is combined with Ibandronate.	Approved
Tetrabenazine	Ibandronate may increase the QTc-prolonging activities of Tetrabenazine.	Approved
Thioridazine	Ibandronate may increase the QTc-prolonging activities of Thioridazine.	Withdrawn
Tiaprofenic acid	The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Ibandronate.	Approved
Tinoridine	The risk or severity of adverse effects can be increased when Tinoridine is combined with Ibandronate.	Investigational
Tobramycin	Tobramycin may increase the hypocalcemic activities of Ibandronate.	Approved, Investigational
Tolfenamic Acid	The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ibandronate.	Approved
Tolmetin	The risk or severity of adverse effects can be increased when Tolmetin is combined with Ibandronate.	Approved
Toremifene	Ibandronate may increase the QTc-prolonging activities of Toremifene.	Approved, Investigational
Tranilast	The risk or severity of adverse effects can be increased when Tranilast is combined with Ibandronate.	Approved, Investigational
Valdecoxib	The risk or severity of adverse effects can be increased when Valdecoxib is combined with Ibandronate.	Investigational, Withdrawn
Valrubicin	Valrubicin may increase the hypocalcemic activities of Ibandronate.	Approved
Vandetanib	Ibandronate may increase the QTc-prolonging activities of Vandetanib.	Approved
Vemurafenib	Ibandronate may increase the QTc-prolonging activities of Vemurafenib.	Approved
Zaltoprofen	The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Ibandronate.	Approved
Zileuton	The risk or severity of adverse effects can be increased when Zileuton is combined with Ibandronate.	Approved, Investigational, Withdrawn
Ziprasidone	Ibandronate may increase the QTc-prolonging activities of Ziprasidone.	Approved
Zomepirac	The risk or severity of adverse effects can be increased when Zomepirac is combined with Ibandronate.	Withdrawn
Zorubicin	Zorubicin may increase the hypocalcemic activities of Ibandronate.	Experimental
Zuclopenthixol	Ibandronate may increase the QTc-prolonging activities of Zuclopenthixol.	Approved, Investigational

Food Interactions

Take on an empty stomach. All foods markedly reduce (up to 90%) ibandronate bioavailabilty. Take with plain water (not mineralized) at least 1 hour before any food. Bioavailability and effect on bone density are both impaired if the patient eats or drinks in less than 1 hour after taking this product. Drink a large glass of water and stay in an upright position for at least 60 minutes after taking this product.

References

Synthesis Reference

Revital Lifshitz-Liron, Thomas Bayer, Judith Aronhime, Michael Pinchasov, "Solid and crystalline ibandronate sodium and processes for preparation thereof." U.S. Patent US20070179119, issued August 02, 2007.

US20070179119

General References

Epstein S, Zaidi M: Biological properties and mechanism of action of ibandronate: application to the treatment of osteoporosis. Bone. 2005 Oct;37(4):433-40. [PubMed:16046205 ]

External Links

Resource	Link
Human Metabolome Database (HMDB)	HMDB14848
PubChem Compound	60852
PubChem Substance	46508134
ChemSpider	54839
BindingDB	12577
ChEMBL	CHEMBL997
Therapeutic Targets Database	DAP001022
PharmGKB	PA10270
HET	BFQ
Drug Product Database	11519
RxList	http://www.rxlist.com/cgi/generic3/boniva.htm
Drugs.com	http://www.drugs.com/cdi/ibandronate.html
Wikipedia	Ibandronate

ATC Codes

M05BA06 — Ibandronic acid

AHFS Codes

92:00

PDB Entries

1YV5

FDA label

Download (296 KB)

MSDS

Download (16 KB)

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Healthy Volunteers	1
1	Completed	Treatment	Healthy Volunteers	1
2	Completed	Treatment	Cancer, Breast	1
2	Completed	Treatment	Pain; Bone Neoplasms; Neoplasm Metastasis	1
2	Recruiting	Treatment	Bone destruction	1
2	Unknown Status	Treatment	Cancer, Breast	1
2	Unknown Status	Treatment	Osteoporosis, Post-Menopausal	1
2	Withdrawn	Treatment	Bone Neoplasms / Neoplasms Metastasis / Pain	1
2, 3	Completed	Treatment	Bone destruction	1
2, 3	Unknown Status	Treatment	Transplant, Kidney	1
3	Active Not Recruiting	Treatment	Cancer, Breast	1
3	Completed	Supportive Care	Malignant Neoplasm of Prostate / Metastatic Cancers / Pain	1
3	Completed	Treatment	Bone Marrow Edema of the Knee / Osteonecrosis of the Knee	1
3	Completed	Treatment	Cancer, Breast	1
3	Completed	Treatment	Haematological Malignancies	1
3	Completed	Treatment	Male Osteoporosis	1
3	Completed	Treatment	Osteoporosis, Post-Menopausal	1
3	Completed	Treatment	Pain; Bone Neoplasms; Neoplasm Metastasis	2
3	Completed	Treatment	Post Menopausal Osteoporosis	3
3	Completed	Treatment	Post-Menopausal Osteopenia	1
3	Completed	Treatment	Postmenopausal Osteoporosis (PMO)	2
3	Completed	Treatment	Postmenopausal Women With Osteoporosis	1
3	Completed	Treatment	Primary Osteoporosis	1
3	Completed	Treatment	Bone destruction	1
3	Terminated	Treatment	Aseptic / Aseptic Hip Necrosis / Hip Necrosis	1
3	Terminated	Treatment	Bone Neoplasms / Neoplasms Metastasis / Pain	2
3	Terminated	Treatment	Multiple Myeloma (MM)	1
3	Unknown Status	Treatment	Cancer, Breast / Hypercalcemia of Malignancy / Metastatic Cancers	1
3	Withdrawn	Supportive Care	Cancer, Breast / Hypercalcemia of Malignancy / Metastatic Cancers / Pain	1
4	Completed	Prevention	Bone destruction / Osteopenia / Rheumatoid Arthritis	1
4	Completed	Treatment	Osteoporosis, Post-Menopausal	3
4	Completed	Treatment	Pain; Bone Neoplasms; Neoplasm Metastasis	2
4	Completed	Treatment	Post Menopausal Osteoporosis	5
4	Completed	Treatment	Post-Menopausal Osteopenia	1
4	Completed	Treatment	Postmenopausal Osteoporosis (PMO)	8
4	Completed	Treatment	Systemic Lupus Erythematosus (SLE)	1
4	Completed	Treatment	Bone destruction	3
4	No Longer Available	Not Available	Postmenopausal Osteoporosis (PMO)	1
4	Suspended	Treatment	Human Immunodeficiency Virus (HIV) Infections	1
4	Terminated	Treatment	Lung Cancers	1
4	Terminated	Treatment	Bone destruction	1
Not Available	Completed	Not Available	Adenocarcinomas / Esophageal Cancers / Squamous Cell Carcinoma (SCC)	1
Not Available	Completed	Not Available	Postmenopausal Osteoporosis (PMO)	1
Not Available	Completed	Not Available	Bone destruction	3
Not Available	Enrolling by Invitation	Not Available	Atypical Femoral Fractures / Bisphosphonate Therapy / Bone destruction	1
Not Available	Withdrawn	Not Available	Cancer, Breast	1

Pharmacoeconomics

Manufacturers

Hoffmann la roche inc

Packagers

Dosage forms

Form	Route	Strength
Injection, solution	Intravenous	3 mg
Tablet, film coated	Oral	150 mg
Liquid	Intravenous	1 mg
Tablet, film coated	Oral	150 mg/1
Injection, solution, concentrate	Intravenous	1 mg
Injection, solution, concentrate	Intravenous	2 mg
Injection, solution, concentrate	Intravenous	6 mg
Tablet, film coated	Oral	50 mg
Injection	Intravenous	3 mg/3mL
Injection, solution	Intravenous	3 mg/3mL
Tablet	Oral	150 mg/1

Prices

Unit description	Cost	Unit
Boniva 3 mg/3ml Kit Box	524.22USD	box
Boniva 3 mg/3 ml syringe	504.06USD	syringe
Boniva 3 150 mg tablet Disp Pack	388.93USD	disp
Boniva 150 mg tablet	124.66USD	tablet
Boniva 2.5 mg tablet	4.16USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
CA2346662	No	2006-05-09	2019-10-01	Canada
US4927814	No	1995-03-17	2012-03-17	US
US6143326	No	1997-04-21	2017-04-21	US
US6294196	No	1999-10-07	2019-10-07	US
US7192938	No	2003-05-06	2023-05-06	US
US7410957	No	2003-05-06	2023-05-06	US
US7718634	No	2003-05-06	2023-05-06	US

Properties

State

Solid

Experimental Properties

Property	Value	Source
water solubility	Freely soluble	Not Available
logP	-2.1	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	13.4 mg/mL	ALOGPS
logP	0.26	ALOGPS
logP	-2.5	ChemAxon
logS	-1.4	ALOGPS
pKa (Strongest Acidic)	0.66	ChemAxon
pKa (Strongest Basic)	9.93	ChemAxon
Physiological Charge	-1	ChemAxon
Hydrogen Acceptor Count	8	ChemAxon
Hydrogen Donor Count	5	ChemAxon
Polar Surface Area	138.53 Å²	ChemAxon
Rotatable Bond Count	9	ChemAxon
Refractivity	71.16 m³·mol^-1	ChemAxon
Polarizability	29.51 Å³	ChemAxon
Number of Rings	0	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	No	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	-	0.9664
Blood Brain Barrier	-	0.5229
Caco-2 permeable	-	0.6012
P-glycoprotein substrate	Substrate	0.6888
P-glycoprotein inhibitor I	Non-inhibitor	0.8195
P-glycoprotein inhibitor II	Non-inhibitor	0.9838
Renal organic cation transporter	Non-inhibitor	0.9092
CYP450 2C9 substrate	Non-substrate	0.8376
CYP450 2D6 substrate	Non-substrate	0.7863
CYP450 3A4 substrate	Non-substrate	0.5504
CYP450 1A2 substrate	Non-inhibitor	0.832
CYP450 2C9 inhibitor	Non-inhibitor	0.8159
CYP450 2D6 inhibitor	Non-inhibitor	0.8987
CYP450 2C19 inhibitor	Non-inhibitor	0.8045
CYP450 3A4 inhibitor	Non-inhibitor	0.8901
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.9945
Ames test	Non AMES toxic	0.6527
Carcinogenicity	Non-carcinogens	0.683
Biodegradation	Not ready biodegradable	0.8346
Rat acute toxicity	2.4278 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.6061
hERG inhibition (predictor II)	Non-inhibitor	0.6622

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum Type	Description	Splash Key
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Positive	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 10V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 20V, Negative	Not Available
Predicted LC-MS/MS	Predicted LC-MS/MS Spectrum - 40V, Negative	Not Available

Taxonomy

Description

This compound belongs to the class of chemical entities known as bisphosphonates. These are organic compounds containing two phosphonate groups linked together through a carbon atoms.

Kingdom

Chemical entities

Super Class

Organic compounds

Class

Organic acids and derivatives

Sub Class

Organic phosphonic acids and derivatives

Direct Parent

Bisphosphonates

Alternative Parents

Organic phosphonic acids / 1,3-aminoalcohols / Trialkylamines / Organopnictogen compounds / Organophosphorus compounds / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives

Substituents

Bisphosphonate / Organophosphonic acid / 1,3-aminoalcohol / Tertiary aliphatic amine / Tertiary amine / Organic nitrogen compound / Organic oxygen compound / Organopnictogen compound / Organic oxide / Hydrocarbon derivative

Molecular Framework

Aliphatic acyclic compounds

External Descriptors

Not Available

Targets

Details

1. Farnesyl pyrophosphate synthase

Kind: Protein
Organism: Human
Pharmacological action: yes
Actions: inhibitor

General Function:: Poly(a) rna binding
Specific Function:: Key enzyme in isoprenoid biosynthesis which catalyzes the formation of farnesyl diphosphate (FPP), a precursor for several classes of essential metabolites including sterols, dolichols, carotenoids, and ubiquinones. FPP also serves as substrate for protein farnesylation and geranylgeranylation. Catalyzes the sequential condensation of isopentenyl pyrophosphate with the allylic pyrophosphates, d...
Gene Name:: FDPS
Uniprot ID:: P14324
Uniprot Name:: Farnesyl pyrophosphate synthase
Molecular Weight:: 48275.03 Da

References

Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Chapurlat RD, Delmas PD: Drug insight: Bisphosphonates for postmenopausal osteoporosis. Nat Clin Pract Endocrinol Metab. 2006 Apr;2(4):211-9; quiz following 238. [PubMed:16932286 ]
Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ: Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001 Feb;296(2):235-42. [PubMed:11160603 ]
Rondeau JM, Bitsch F, Bourgier E, Geiser M, Hemmig R, Kroemer M, Lehmann S, Ramage P, Rieffel S, Strauss A, Green JR, Jahnke W: Structural basis for the exceptional in vivo efficacy of bisphosphonate drugs. ChemMedChem. 2006 Feb;1(2):267-73. [PubMed:16892359 ]

Details

2. Hydroxylapatite

Kind: Small molecule
Organism: Human
Pharmacological action: yes
Actions: antagonist

References

Jahnke W, Henry C: An in vitro assay to measure targeted drug delivery to bone mineral. ChemMedChem. 2010 May 3;5(5):770-6. doi: 10.1002/cmdc.201000016. [PubMed:20209564 ]
Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH: Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006 May;38(5):617-27. Epub 2005 Jul 20. [PubMed:16046206 ]

Drug created on June 13, 2005 07:24 / Updated on July 25, 2017 17:53

Get DrugBank to go!

Structure for DB00710 (Ibandronate)

Targets

References

References